@ISNEDUCATION WEBINAR: COVID-19 vaccination in immune-mediated kidney diseases


@ISNeducation Webinar: COVID-19 vaccination in immune-mediated kidney diseases

COVID vaccination webinar kidney disease

SARS-CoV-2 (COVID-19) vaccine platforms are becoming available and are the most promising strategy to curb the spread of SARS-CoV-2 infections. However, numerous uncertainties exist regarding the pros and cons of vaccination, especially in patients with (immune-mediated) kidney diseases on immunosuppressive drugs. For instance, post-marketing surveillance should be performed to estimate the rate of vaccine response (humoral and cellular) of different vaccine platforms, and surveillance of disease activity following administration of COVID-19 vaccines. Some of the candidates induce signaling pathways which also promote autoimmune kidney diseases, e.g. type I interferons in systemic lupus erythematosus. Efficacy estimates would thus far favor the use of selected COVID-19 vaccines, such as BNT162b2, mRNA-1273 or Gam-COVID-Vac. Also, humoral immune response after vaccination should be monitored using appropriate assays. Even in the absence of neutralizing antibodies patients might be protected by a sufficient cellular immune response capable to reduce severity of COVID-19. A reduced vaccine response after the use of CD20-depleting agents is anticipated, and it is particularly important to discuss strategies to improve vaccine response with these patients.

Learning objectives:

13 frequently-asked questions regarding safety and efficacy of the most promising vaccine candidates will be discussed.

Take the quiz

@ISNeducation Webinar: COVID-19 vaccination in immune-mediated kidney diseases

27/5/20213:00pm CEST1 hour

Convert to my timezone